OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs

OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment

Beerse, Belgium, 25 September 2019 – OCTIMET Oncology NV, the Belgian life science company with a focus on accelerated development of highly selective differentiated MET kinase inhibitors is pleased to announce the recruitment of the first patient into the second module of its phase I/II clinical study in patients with advanced solid malignancies.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH